Inoviq Ltd
IIQ
Company Profile
Business description
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.
Contact
23 Normanby Road
Notting Hill
MelbourneVIC3168
AUST: +61 395487586
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
stocks
Market overreacts to soft guidance from ASX share
Shares undervalued after they plunge following results.
stocks
CBA earnings: The only thing that puzzles us is the share price
No surprises in fiscal 2025 earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.10 | 46.00 | 0.51% |
| CAC 40 | 7,804.97 | 51.55 | 0.66% |
| DAX 40 | 24,185.59 | 160.81 | 0.67% |
| Dow JONES (US) | 44,922.27 | 463.66 | 1.04% |
| FTSE 100 | 9,166.21 | 0.98 | 0.01% |
| HKSE | 25,493.66 | 120.01 | -0.47% |
| NASDAQ | 21,713.14 | 31.24 | 0.14% |
| Nikkei 225 | 42,649.26 | 625.41 | -1.45% |
| NZX 50 Index | 12,834.08 | 67.54 | 0.53% |
| S&P 500 | 6,466.58 | 20.82 | 0.32% |
| S&P/ASX 200 | 8,873.80 | 46.70 | 0.53% |
| SSE Composite Index | 3,667.53 | 15.94 | -0.43% |